Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mojun Zhu

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Gastrointestinal Oncology|July 11, 2026
Efficacy and safety of modified FLOT chemotherapy in gastric or gastroesophageal junction adenocarcinoma: a retrospective cohort studyCody Eslinger, Oudai Sahwan, Fares Jamal, et al.
JCO Precision Oncology|March 25, 2026
Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal CarcinomaFares Jamal, Oudai Sahwan, Seyi Abidoye, et al.
Cancer Chemotherapy and Pharmacology|February 26, 2021
A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancersWen Wee Ma, Mojun Zhu, Elaine T Lam, et al.
JCO Precision Oncology|November 20, 2025
Immune Checkpoint Inhibitors for Mismatch Repair-Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo ClinicOudai Sahwan, Fares Jamal, Rish Pai, et al.
Advanced Biology|March 28, 2022
Understanding Suboptimal Response to Immune Checkpoint InhibitorsMojun Zhu, Henan Zhang, Katrina S Pedersen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal JunctionMojun Zhu, Chunhua Chen, Nathan R Foster, et al.
JCI Insight|October 18, 2022
Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancersTara L Hogenson, Hao Xie, William J Phillips, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Gastrointestinal Oncology|July 11, 2026
Efficacy and safety of modified FLOT chemotherapy in gastric or gastroesophageal junction adenocarcinoma: a retrospective cohort studyCody Eslinger, Oudai Sahwan, Fares Jamal, et al.
JCO Precision Oncology|March 25, 2026
Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal CarcinomaFares Jamal, Oudai Sahwan, Seyi Abidoye, et al.
Cancer Chemotherapy and Pharmacology|February 26, 2021
A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancersWen Wee Ma, Mojun Zhu, Elaine T Lam, et al.
JCO Precision Oncology|November 20, 2025
Immune Checkpoint Inhibitors for Mismatch Repair-Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo ClinicOudai Sahwan, Fares Jamal, Rish Pai, et al.
Advanced Biology|March 28, 2022
Understanding Suboptimal Response to Immune Checkpoint InhibitorsMojun Zhu, Henan Zhang, Katrina S Pedersen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal JunctionMojun Zhu, Chunhua Chen, Nathan R Foster, et al.
JCI Insight|October 18, 2022
Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancersTara L Hogenson, Hao Xie, William J Phillips, et al.
Pageof 3